These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives. Rotondo C; Lopalco G; Iannone F; Vitale A; Talarico R; Galeazzi M; Lapadula G; Cantarini L Mediators Inflamm; 2015; 2015():451675. PubMed ID: 26185360 [TBL] [Abstract][Full Text] [Related]
4. Current therapy for Behçet's disease. Goker B; Goker H Am J Ther; 2002; 9(5):465-70. PubMed ID: 12237740 [TBL] [Abstract][Full Text] [Related]
10. Adamantiades-Behçet Disease at the Beginning of the Silk Route: North-East Italian Experience. Bergamo S; di Meo N; Stinco G; Bonin S; Trevisini S; Trevisan G Acta Dermatovenerol Croat; 2017 Dec; 25(4):295-297. PubMed ID: 30064603 [TBL] [Abstract][Full Text] [Related]
11. Behçet's disease: New insights into pathophysiology, clinical features and treatment options. Greco A; De Virgilio A; Ralli M; Ciofalo A; Mancini P; Attanasio G; de Vincentiis M; Lambiase A Autoimmun Rev; 2018 Jun; 17(6):567-575. PubMed ID: 29631062 [TBL] [Abstract][Full Text] [Related]
12. Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease. Park JY; Chung YR; Lee K; Song JH; Lee ES Yonsei Med J; 2015 Jul; 56(4):1158-62. PubMed ID: 26069144 [TBL] [Abstract][Full Text] [Related]
14. Behçet's disease. Report of twenty-five patients from the United States with prominent mucocutaneous involvement. Mangelsdorf HC; White WL; Jorizzo JL J Am Acad Dermatol; 1996 May; 34(5 Pt 1):745-50. PubMed ID: 8632067 [TBL] [Abstract][Full Text] [Related]
16. The multiple faces of Behçet's disease and its aetiological factors. Onder M; Gürer MA J Eur Acad Dermatol Venereol; 2001 Mar; 15(2):126-36. PubMed ID: 11495519 [TBL] [Abstract][Full Text] [Related]
17. [Ocular manifestations in Behçet's disease]. Desbois AC; Terrada C; Cacoub P; Bodaghi B; Saadoun D Rev Med Interne; 2018 Sep; 39(9):738-745. PubMed ID: 29625716 [TBL] [Abstract][Full Text] [Related]
18. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature. Hatemi I; Hatemi G; Pamuk ON; Erzin Y; Celik AF Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S129-37. PubMed ID: 26486925 [TBL] [Abstract][Full Text] [Related]